The diagnosis and management of multiple sclerosis

Acta Neurologica Scandinavica

Volumn 112, Issue 3, 2005, Pages 199-201

  Poser, C M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTVACCINAL ENCEPHALITIS;

HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 23844444503     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00450.x     Document Type: Note

References (20)

1. YOUNG I, HALL A, PALLIS C et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981;2:1063-6.
2. MCDONALD W, COMPSTON D, EDAN G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
3. BARKHOF F, FILIPPI M, MILLER D et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69.
4. KESSELRING J, MILLER D, ROBB S et al. Acute disseminated encephalomyelitis. MRI imaging and distinction from multiple sclerosis. Brain 1990;113:291-302.
5. TRIULZI F, SCOTTI G. Differential diagnosis of multiple sclerosis: contribution of magnetic resonance techniques. J Neurol Neurosurg Psychiatry 1998;64 (Suppl.):S6-14.
6. POSER C. An Atlas of Multiple Sclerosis. Carnsworth, UK: Parthenon Publishing, 1998.
7. BRINAR V. The differential diagnosis of multiple sclerosis. Clin Neurol Neurosurg 2002;104:211-20.
8. POSER C. Misdiagnosis of multiple sclerosis and β-interferon. Lancet 1997;349:1915.
9. MIRSATTARI S, JOHNSON J, MCKENNA R et al. Aboriginals with multiple sclerosis. HLA types and predominance of neuromyelitis optica. Neurology 2001;56:317-23.
10. LUCCHINETTI C, BRÜCK W, PARISI J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
11. RODRIGUEZ M, SCHEITHAUER B, FORBES G et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-36.
12. BRÜCK W, BITSCH A, KOLENDA H et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-93.
13. POSER C. The pathogenesis of multiple sclerosis: a commentary. Clin Neurol Neurosurg 2000;102:191-4.
14. COMPSTON D, COLES A. Multiple sclerosis. Lancet 2002;359:1221-31.
15. JACOBS L, BECK R, SIMON J et al. Intramuscular interferon beta-1a therapy initiated during the first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
16. COMI G, FILIPPI M, BARKHOF F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001;357:1576-82.
17. FILIPPI M, ROVARIS M, INGLESE M et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet 2004;364:1489-96.
18. CONFAVREUX C, VUKUSIC S, ADELEINE P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-82.
19. FILIPPINI G, MUNARI L, INCORVAIS B et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52.
20. GOODIN D, KAPPOS L, PATY D et al. Interferons in relapsing remitting multiple sclerosis. Lancet 2003;361:1821-5.